LANDOS BIOPHARMA Revenue and Competitors

Landos Biopharma is a clinical-stage biopharmaceutical company focused on the discovery and development of first-in-class oral therapeutics for patients with autoimmune disease. BT-11, Landos' lead asset, is completing a Phase 2 trial in mild to moderate ulcerative colitis (UC) in the U.S. Europe and Russia, with plans to initiate a Phase 2 trial of BT-11 in moderate to severe Crohn's disease (CD). BT-11 is a small molecule that targets a novel immunometabolic pathway within the gastrointestinal tract, potentially providing a more effective treatment and an improved patient tolerability profile.